PLoS Pathogens· 2026Q1
Dual plasmepsin IX and X inhibitors are refractory to development of resistance
- 2citations
- Q1SCImago
- 2026year
Short summary
Dual plasmepsin IX/X (PMIX/X) inhibitors for malaria treatment could not be selected for resistance, even under prolonged pressure, unlike PMX-selective inhibitors which showed reduced sensitivity via gene amplification and mutations.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Public Health, Environmental and Occupational Health
Public Health, Environmental and Occupational HealthMedicine